US2015335656A1PendingUtilityA1
Antitumor agent
Assignee: MITSUBISHI TANABE PHARMA CORPPriority: Dec 28, 2007Filed: Aug 5, 2015Published: Nov 26, 2015
Est. expiryDec 28, 2027(~1.4 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00A61K 31/551C07D 495/14A61K 31/5517
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal.
Claims
exact text as granted — not AI-modified1 . A method of inhibiting the growth of cancer cells in a mammal, comprising administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate thereof to the mammal.
Join the waitlist — get patent alerts
Track US2015335656A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.